Literature DB >> 16202968

A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations.

Shabnam Lainwala1, Elizabeth R Brown, Nancy P Weinschenk, Mary T Blackwell, James I Hagadorn.   

Abstract

PURPOSE: Length of hospital stay (LOS) of infants treated for neonatal abstinence syndrome (NAS) with methadone was compared to LOS of those treated with an oral morphine preparation (OMP, neonatal morphine solution, or deodorized tincture of opium).
METHODS: A retrospective review of medical records of infants treated for NAS due to in utero exposure to methadone and/or illicit drugs such as heroin or morphine was performed for birthweight, neonatal abstinence scores, infant and maternal illicit drug exposure history, maternal methadone dose (if any), and details of treatment. Length of stay was the primary outcome measure.
RESULTS: Forty-six infants met the inclusion criteria. The median LOS of infants treated with methadone versus OMP was not significant (P > 0.05). Prolonged LOS was associated with larger pharmacological treatment doses required to control withdrawal symptoms, larger maternal methadone dose, and increased birthweight. After adjusting for these factors, exposure to opioids in utero, maternal nicotine use, hospital of treatment, severity of withdrawal symptoms, and foster care placement were not significantly associated with LOS in univariate or multivariate analyses.
CONCLUSIONS: These results suggest that infants treated with OMP or methadone have similar LOS. Longer LOS is associated with both higher maternal methadone doses and higher opioid treatment dose requirements after birth. The potential effect of maternal methadone dose on neonatal LOS should be considered when treating expectant mothers on methadone maintenance therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16202968     DOI: 10.1016/j.adnc.2005.06.003

Source DB:  PubMed          Journal:  Adv Neonatal Care        ISSN: 1536-0903            Impact factor:   1.968


  26 in total

1.  Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.

Authors:  Walter K Kraft; Kevin Dysart; Jay S Greenspan; Eric Gibson; Karol Kaltenbach; Michelle E Ehrlich
Journal:  Addiction       Date:  2010-10-06       Impact factor: 6.526

Review 2.  Fetal effects of psychoactive drugs.

Authors:  Amy L Salisbury; Kathryn L Ponder; James F Padbury; Barry M Lester
Journal:  Clin Perinatol       Date:  2009-09       Impact factor: 3.430

Review 3.  Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS).

Authors:  A K Mangat; G M Schmölzer; W K Kraft
Journal:  Semin Fetal Neonatal Med       Date:  2019-02-05       Impact factor: 3.926

4.  Early Intervention Referral and Enrollment Among Infants with Neonatal Abstinence Syndrome.

Authors:  Elizabeth Peacock-Chambers; JoAnna K Leyenaar; Sheila Foss; Emily Feinberg; Donna Wilson; Peter D Friedmann; Paul Visintainer; Rachana Singh
Journal:  J Dev Behav Pediatr       Date:  2019 Jul/Aug       Impact factor: 2.225

5.  Variation in treatment of neonatal abstinence syndrome in US children's hospitals, 2004-2011.

Authors:  S W Patrick; H C Kaplan; M Passarella; M M Davis; S A Lorch
Journal:  J Perinatol       Date:  2014-06-12       Impact factor: 2.521

6.  Neonatal withdrawal syndrome, Michigan, 2000-2009.

Authors:  Kimberly A Hekman; Violanda I Grigorescu; Lorraine L Cameron; Corinne E Miller; Ruben A Smith
Journal:  Am J Prev Med       Date:  2013-07       Impact factor: 5.043

7.  Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting.

Authors:  C H Backes; C R Backes; D Gardner; C A Nankervis; P J Giannone; L Cordero
Journal:  J Perinatol       Date:  2011-08-18       Impact factor: 2.521

Review 8.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

9.  An Initiative to Improve the Quality of Care of Infants With Neonatal Abstinence Syndrome.

Authors:  Matthew R Grossman; Adam K Berkwitt; Rachel R Osborn; Yaqing Xu; Denise A Esserman; Eugene D Shapiro; Matthew J Bizzarro
Journal:  Pediatrics       Date:  2017-05-18       Impact factor: 7.124

10.  Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.

Authors:  Walter K Kraft; Eric Gibson; Kevin Dysart; Vidula S Damle; Jennifer L Larusso; Jay S Greenspan; David E Moody; Karol Kaltenbach; Michelle E Ehrlich
Journal:  Pediatrics       Date:  2008-08-11       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.